Overexpression of MYBL2 Promotes Proliferation and Migration of Non-small-cell Lung Cancer Via Upregulating NCAPH

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2020 Mar 23

PMID 32200471

Citations 25

Authors

Yu-Chao Xiong

Jiao Wang

Yong Cheng

Xin-Yi Zhang

Xiao-Qun Ye

Affiliations

Soon will be listed here.

Abstract

MYB Proto-Oncogene Like 2 (MYBL2) is a highly conserved member of the Myb family of transcription factors and plays a critical role in regulating cell proliferation and survival. Here we show that overexpression of MYBL2 is frequently observed in lung adenocarcinoma (LUAD) and significantly correlates with advanced stage and poor patient survival. Knockdown of MYBL2 induced apoptosis in lung cancer cells and resulted in significant inhibition of cell proliferation, migration, and invasion. Notably, we identified Non-SMC Condensin I Complex Subunit H (NCAPH) gene as a direct target of MYBL2. NCAPH expression is highly correlated with that of MYBL2 in LUAD cases and is tightly affected by MYBL2 knockdown or overexpression in vitro. Chromatin immunoprecipitation (ChIP) assays also showed that MYBL2 directly binds to the transcription start site (TSS) of NCAPH. Moreover, we provided evidence that NCAPH functions as an oncogene in lung cancer and overexpression of NCAPH could partially rescue cell death and migration blockage induced by MYBL2 knockdown. Together, these results suggest that overexpression of MYBL2 promotes proliferation and migration of lung cancer cells via upregulating NCAPH, establishing their roles as novel prognostic biomarkers as well as potential therapeutic targets for the disease.

Citing Articles

Multi-omics characterization and machine learning of lung adenocarcinoma molecular subtypes to guide precise chemotherapy and immunotherapy.

Zhang Y, Wang Y, Qian H Front Immunol. 2024; 15:1497300.

PMID: 39669580 PMC: 11634853. DOI: 10.3389/fimmu.2024.1497300.

Genome-wide binding analysis unveils critical implication of B-Myb-mediated transactivation in cancers.

Tao C, Liu T, Zhao Z, Dou X, Xia X, Du K Int J Biol Sci. 2024; 20(12):4691-4712.

PMID: 39309447 PMC: 11414393. DOI: 10.7150/ijbs.92607.

QIGTD: identifying critical genes in the evolution of lung adenocarcinoma with tensor decomposition.

Chen B, Zhang J, Shao C, Bian J, Kang R, Shang X BioData Min. 2024; 17(1):30.

PMID: 39232802 PMC: 11376055. DOI: 10.1186/s13040-024-00386-w.

A comprehensive review on lncRNA LOXL1-AS1: molecular mechanistic pathways of lncRNA LOXL1-AS1 in tumorigenicity of cancer cells.

Yousefnia S Front Oncol. 2024; 14:1384342.

PMID: 39136001 PMC: 11317273. DOI: 10.3389/fonc.2024.1384342.

MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with TMB in pancreatic cancer.

Li Y, Wang S, Guo M, Yang R, Wei X, Li H J Cancer. 2024; 15(13):4360-4373.

PMID: 38947375 PMC: 11212096. DOI: 10.7150/jca.96320.

References

Arai T, Kojima S, Yamada Y, Sugawara S, Kato M, Yamazaki K . Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: Regulation of NCAPH by antitumor miR-199a/b-3p. Int J Urol. 2019; 26(4):506-520. DOI: 10.1111/iju.13911. View

Sala A . c-MYB and TGFβ: EMT's dynamic duo in breast cancer. Cell Cycle. 2011; 11(1):17. DOI: 10.4161/cc.11.1.18733. View

Chen J, Chen X . MYBL2 Is Targeted by miR-143-3p and Regulates Breast Cancer Cell Proliferation and Apoptosis. Oncol Res. 2017; 26(6):913-922. PMC: 7844795. DOI: 10.3727/096504017X15135941182107. View

Lorvellec M, Dumon S, Maya-Mendoza A, Jackson D, Frampton J, Garcia P . B-Myb is critical for proper DNA duplication during an unperturbed S phase in mouse embryonic stem cells. Stem Cells. 2010; 28(10):1751-9. PMC: 4214134. DOI: 10.1002/stem.496. View

Heinrichs S, Conover L, Bueso-Ramos C, Kilpivaara O, Stevenson K, Neuberg D . MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife. 2013; 2:e00825. PMC: 3713455. DOI: 10.7554/eLife.00825. View

Shi H, Bevier M, Johansson R, Enquist-Olsson K, Henriksson R, Hemminki K . Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer. Breast Cancer Res Treat. 2011; 131(3):1039-47. DOI: 10.1007/s10549-011-1826-2. View

Guan Z, Cheng W, Huang D, Wei A . High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma. Curr Res Transl Med. 2017; 66(1):27-32. DOI: 10.1016/j.retram.2017.11.002. View

Sandberg M, Sutton S, Pletcher M, Wiltshire T, Tarantino L, Hogenesch J . c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell. 2005; 8(2):153-66. DOI: 10.1016/j.devcel.2004.12.015. View

Clarke M, Dumon S, Ward C, Jager R, Freeman S, Dawood B . MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia. Leukemia. 2012; 27(3):661-70. PMC: 3593183. DOI: 10.1038/leu.2012.241. View

10.

Yin L, Jiang L, Shen Q, Xiong Q, Zhuo X, Zhang L . NCAPH plays important roles in human colon cancer. Cell Death Dis. 2017; 8(3):e2680. PMC: 5386579. DOI: 10.1038/cddis.2017.88. View

11.

Cui F, Hu J, Xu Z, Tan J, Tang H . Overexpression of NCAPH is upregulated and predicts a poor prognosis in prostate cancer. Oncol Lett. 2019; 17(6):5768-5776. PMC: 6507296. DOI: 10.3892/ol.2019.10260. View

12.

Shimomura H, Sasahira T, Nakashima C, Kurihara-Shimomura M, Kirita T . Non-SMC Condensin I Complex Subunit H (NCAPH) Is Associated with Lymphangiogenesis and Drug Resistance in Oral Squamous Cell Carcinoma. J Clin Med. 2020; 9(1). PMC: 7019401. DOI: 10.3390/jcm9010072. View

13.

Jia Y, Gao Y, Li J, Chang Z, Yan J, Qin Y . Prognostic implications of MYBL2 in resected Chinese gastric adenocarcinoma patients. Onco Targets Ther. 2019; 12:1129-1135. PMC: 6376880. DOI: 10.2147/OTT.S188820. View

14.

Shao M, Ren Z, Zhang R . MYBL2 protects against H9c2 injury induced by hypoxia via AKT and NF‑κB pathways. Mol Med Rep. 2018; 17(3):4832-4838. DOI: 10.3892/mmr.2018.8387. View

15.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

16.

Frau M, Ladu S, Calvisi D, Simile M, Bonelli P, Daino L . Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype. J Hepatol. 2011; 55(1):111-9. DOI: 10.1016/j.jhep.2010.10.031. View

17.

Ward C, Volpe G, Cauchy P, Ptasinska A, Almaghrabi R, Blakemore D . Fine-Tuning Mybl2 Is Required for Proper Mesenchymal-to-Epithelial Transition during Somatic Reprogramming. Cell Rep. 2018; 24(6):1496-1511.e8. PMC: 6092268. DOI: 10.1016/j.celrep.2018.07.026. View

18.

Fan X, Wang Y, Jiang T, Cai W, Jin Y, Niu Y . B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3. Int J Mol Sci. 2018; 19(5). PMC: 5983693. DOI: 10.3390/ijms19051479. View

19.

Ahmed F . Integrated Network Analysis Reveals FOXM1 and MYBL2 as Key Regulators of Cell Proliferation in Non-small Cell Lung Cancer. Front Oncol. 2019; 9:1011. PMC: 6804573. DOI: 10.3389/fonc.2019.01011. View

20.

Musa J, Aynaud M, Mirabeau O, Delattre O, Grunewald T . MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017; 8(6):e2895. PMC: 5520903. DOI: 10.1038/cddis.2017.244. View